Shay Ben-Sasson
Epilepsy affects over 50 million people worldwide, including 3.4 million in the U.S, yet it remains under-recognized and under-treated. About 30% of patients have drug-resistant Epilepsy (DRE)—meaning seizures persist despite medication WHO Fact Sheet. The consequences are far-reaching: many live in fear of the next seizure, especially at night. Caregivers, often family members, report high fatigue (85%) and poor sleep (68%), driven by the constant need to stay alert Epilepsy Research and Treatment.
Epilepsy is also deadly, where about 1 to 1,000 suffer from Sudden Unexpected Death in Epilepsy (SUDEP) annually CDC. The risk of SUDEP is significantly higher at night and in individuals who sleep alone. Studies show that people with nocturnal seizures who do not share a bedroom face up to a 67-fold increased risk of SUDEP, while those with caregivers or nocturnal supervision have notably lower risk Cure Epilepsy. This highlights the urgent need for real-time monitoring and predictive technologies.
While the global epilepsy treatment market reached approximately $11.85 billion in 2024, with projections estimating growth to $11.85 billion by 2033 at a CAGR of 4.57%, the majority of these treatments remain pharmaceutical Business Wire Report. However, a significant and growing segment of the market is shifting towards technology-driven solutions, particularly wearable monitors and smart diagnostics. The epilepsy monitoring devices market is experiencing notable growth, driven by the increasing prevalence of epilepsy, advancements in monitoring technologies, and a rising demand for continuous, real-time patient monitoring. In 2023, this market was valued at $559 million and is projected to reach $874.4 million by 2030, growing at a CAGR of 6.6% Grand View Research Report.
Recent surveys reveal a strong and growing demand for wearable seizure detection devices among both people with epilepsy and their caregivers. In a study published in Epilepsy & Behavior, over 80% of patients expressed interest in using wearables to monitor seizures, highlighting the potential of these tools to increase safety, improve condition awareness, and offer greater independence. This need is particularly acute at night, when seizures often go unnoticed and caregivers experience significant sleep disruption and anxiety. Clinical studies on night-use devices, such as the NightWatch system, have shown that real-time alerts during major nocturnal seizures can significantly improve safety and reduce SUDEP risk NightWatch. These insights underscore the importance of reliable, easy-to-use, overnight EEG solutions—helping families sleep easier and patients stay protected during their most vulnerable hours.
NeuroHelp is helping to close the gap with Epiness™—a wearable EEG system powered by AI that can predict seizures up to an hour in advance. Designed for home use, it provides early alerts that give patients time to prepare, intervene, or get to safety. For millions living with unpredictable seizures, Epiness represents more than a medical device—it's a step toward peace of mind, autonomy, and better outcomes. As we bring this solution to market, our goal is clear: to give epilepsy patients control where they've long had uncertainty.